Wyeth Shifting R&D Funds To Early-Stage Compound Research And Licensing
Executive Summary
Wyeth is moving R&D spend from Phase III projects to discovery and early stage programs in an effort to continue meeting its goal of submitting two NDAs for new molecular entities per year, R&D President Robert Ruffolo said
You may also be interested in...
Wyeth’s R&D Strategy: Spoonfuls Of Enrollment With A Dash Of Outsourcing
Wyeth research and development efforts are focusing on global patient enrollment as a key method to accelerate the drug development process
Wyeth’s R&D Strategy: Spoonfuls Of Enrollment With A Dash Of Outsourcing
Wyeth research and development efforts are focusing on global patient enrollment as a key method to accelerate the drug development process
Enhanced Phase II Efforts Paying Dividends, But At A Price, Pfizer Exec Says
Expanded approaches to Phase II development have reduced Phase III attrition rates, but in doing so, have also created a new set of challenges for pharmaceutical companies, according to Pfizer Senior VP-Science & Technology Peter Corr